Publications
323
Citations
4,635
Est. group size
~1
Recurring co-author estimate
Active years
39
Publishing since 1988
Typically publishes in teams of ~28 · 3% small-team papers (≤3 authors) · across 55 venues
- Transcriptomic, Genomic, and Clinical Characterization of Morphological Classes in Localized and Metastatic Pancreatic Cancer
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- Developing design guidelines for controlling charge transport in DNA
Nature Chemistry · 2025
- Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil
The Lancet Regional Health - Americas · 2025
- Antispike IgG antibody decay after immunisation with fractional versus full booster doses of COVID-19 vaccines: a 6-month longitudinal analysis of the FRACT-COV trial in Brazil
BMJ Public Health · 2025
- NeoPancONE: GATA6 expression as a predictor of benefit to peri-operative modified FOLFIRINOX in resectable pancreatic adenocarcinoma (r-PDAC): A multicentre phase II study.
Journal of Clinical Oncology · 2025
- Integrative analysis of tumor microenvironment in advanced pancreatic cancer: Unraveling genomic and immune landscape for targeted therapies.
Journal of Clinical Oncology · 2025
- Commensal-derived Trehalose Monocorynomycolate Triggers γδ T Cell-driven Protective Ocular Barrier Immunity
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- StitchLLM: Serving LLMs, One Block at a Time
2025
- Gut microbiota drive autoimmunity to neuroretina in a humanized gnotobiotic mouse model of spontaneous autoimmune uveitis 9300
The Journal of Immunology · 2025
- Supplementary Figures S1-S2 from hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma
2025
- Supplementary table 3 from Spectrum of Response to Platinum and PARP Inhibitors in Germline <i>BRCA</i>–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
2025
- Supplementary figure 2 from Spectrum of Response to Platinum and PARP Inhibitors in Germline <i>BRCA</i>–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
2025
- Supplementary figure 1 from Spectrum of Response to Platinum and PARP Inhibitors in Germline <i>BRCA</i>–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
2025
- Supplementary table 2 from Spectrum of Response to Platinum and PARP Inhibitors in Germline <i>BRCA</i>–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
2025
- Supplementary table 1 from Spectrum of Response to Platinum and PARP Inhibitors in Germline <i>BRCA</i>–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
2025
- Journal of Clinical Oncology×19
- arXiv (Cornell University)×10
- Cancer Research×10
- bioRxiv (Cold Spring Harbor Laboratory)×7
- Clinical Cancer Research×6
- Susan Tsai
Medicine · The Ohio State University
- Jamie N. Mills
Medicine · University of Michigan
- Sarah Nelson
Medicine · University of Michigan
- Ashish Manne
Medicine · The Ohio State University
- Ankur Sheel
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile